Abbott (NYSE: ABT), CamDiab and Ypsomed today announced that they are partnering to develop and commercialize an integrated automated insulin delivery (AID) system to help lessen the burden of round-the-clock diabetes management for people with diabetes. The initial focus of the partnership will be in European .
/PRNewswire/ Abbott (NYSE: ABT), CamDiab and Ypsomed today announced that they are partnering to develop and commercialize an integrated automated insulin.